8-K: Black Diamond Therapeutics Announces 2025 Annual Meeting Results, Elects Class II Directors and Ratifies Auditor

Black Diamond Therapeutics, Inc. announced the final voting results from its 2025 Annual Meeting of Stockholders, confirming the election of three Class II directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor.

Summary

• Black Diamond Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders virtually on June 12, 2025.
• As of the record date of April 14, 2025, 56,676,716 shares of common stock were outstanding and entitled to vote.
• A quorum was established with 42,988,581 shares represented at the meeting.
• Stockholders voted on two proposals detailed in the Proxy Statement filed on April 18, 2025.
• Proposal No. 1 involved the election of three Class II director nominees to the Board of Directors for three-year terms until the 2028 annual meeting.
• Ali Behbahani was elected with 14,529,061 votes FOR, 19,960,856 WITHHELD, and 8,498,664 BROKER NON-VOTES.
• Garry E. Menzel was elected with 33,533,241 votes FOR, 956,676 WITHHELD, and 8,498,664 BROKER NON-VOTES.
• Samarth Kulkarni was elected with 14,217,936 votes FOR, 20,271,981 WITHHELD, and 8,498,664 BROKER NON-VOTES.
• Proposal No. 2 ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The auditor ratification passed with 42,483,483 votes FOR, 445,873 AGAINST, and 59,225 ABSTAIN.
• All matters submitted to a vote of security holders were approved.

Sentiment

Score: 6

Explanation: The overall sentiment is moderately positive as all proposals passed, ensuring corporate continuity. However, the significant 'WITHHELD' votes for two director nominees introduce a degree of underlying shareholder dissent, preventing a higher score.

Positives

• A quorum was successfully established for the Annual Meeting, indicating sufficient shareholder participation.
• Both key proposals, the election of Class II directors and the ratification of the independent auditor, were approved by stockholders.
• Garry E. Menzel received strong shareholder support with 33,533,241 votes FOR his re-election.
• The appointment of PricewaterhouseCoopers LLP as the independent auditor was overwhelmingly ratified with 42,483,483 votes FOR, demonstrating strong confidence in the firm.

Negatives

• Ali Behbahani and Samarth Kulkarni each received a significant number of 'WITHHELD' votes (19,960,856 and 20,271,981 respectively), which exceeded their 'FOR' votes, indicating notable shareholder dissent or lack of support for their re-election.

Future Outlook

No specific forward-looking statements or guidance were provided in this document beyond the terms of service for the elected directors and ratified auditor.

Industry Context

This 8-K filing details the routine outcomes of an annual stockholder meeting, a standard corporate governance event for publicly traded companies. It reflects compliance with SEC regulations regarding shareholder voting and does not provide specific insights into broader industry trends or competitive landscape.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the voting results, particularly the election of directors and ratification of the auditor, which affect corporate governance and oversight. The significant 'WITHHELD' votes for two directors may signal areas of shareholder concern.

Next Steps

• The elected Class II directors will serve for a three-year term until the Company's 2028 annual meeting of stockholders.
• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, SEC filing, 8-K, Annual Meeting, Stockholders, Director Election, Corporate Governance, PricewaterhouseCoopers, Auditor Ratification, Proxy Statement, Nasdaq